NASDAQ · LIXT
Lixte Biotechnology Holdings, Inc.
$7.21-$0.46 (-6.0%)
Lixte Biotechnology Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.96% below the high.
Loading market information…
OTC · PTPI · USD
Stock price, earnings
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Petros Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Petros Pharmaceuticals, Inc.’s next earnings report is currently expected on Dec 2, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Petros Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 | Nov 13, 2024 | -$13.25-4,468.97% vs estimate | $1.68M+25.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.21-$0.46 (-6.0%)
Lixte Biotechnology Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.96% below the high.
$0.80-$0.05 (-5.79%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.62% below the high.
$0.68+$0.00 (+0.15%)
PetVivo Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.6% below the high.
$0.90+$0.17 (+23.12%)
Syra Health Corp. Class A Common Stock’s quoted price sits in the upper half of its reported 52-week range, 21.74% below the high.
$1.91-$0.23 (-10.93%)
INVO Fertility, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.2% below the high.
$0.18+$0.04 (+28.57%)
Hepion Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
$0.02$0.00 (0.0%)
Peak Bio, Inc.: Healthcare · Biotechnology.
$3.57-$0.09 (-2.46%)
Concord Medical Services Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 47.5% below the high.
